Search
Results: 3
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1)
Elizabeth Smyth, Maren Knödler, Anne Giraut, Murielle Mauer, Magnus Nilsson, Nicole Van Grieken, Anna Dorothea Wagner, Markus Moehler, Florian Lordick
Mar 25, 2020
Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse...
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1)
Elizabeth Smyth, Maren Knödler, Anne Giraut, Murielle Mauer, Magnus Nilsson, Nicole Van Grieken, Anna Dorothea Wagner, Markus Moehler, Florian Lordick
Feb 13, 2020
Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse...
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers.
Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal cancer, this class of drugs have demonstrated durable responses and survival benefit in a subgroup of patients, resulting in regulatory...